Spatial Domains
Dominant neighborhood compartment and purity from Tier 1 domain summaries. Bulk files are centralized on the Download page.
1,351-1,400 of 2,070
Spatial Domains
Dominant neighborhood compartment and purity from Tier 1 domain summaries.
2,069 ready
| Sample | Organ | Disease state | Cells | Dominant compartment ?Largest Tier 1 spatial domain by sample fraction; this is a biological neighborhood label, not a row-count summary. | Domain share | Purity | Diversity |
|---|---|---|---|---|---|---|---|
| NSCLC_38242124__IMC__86_C8,2 | Lung | Primary cancer | 3,875 | Tumor/Malignant | 38.1% | 0.92 | 0.27 |
| NSCLC_38242124__IMC__86_C8,4 | Lung | Primary cancer | 2,468 | Stromal | 35.4% | 0.83 | 0.46 |
| NSCLC_38242124__IMC__86_C8,7 | Lung | Primary cancer | 2,709 | Tumor/Malignant | 53.7% | 0.99 | 0.05 |
| NSCLC_38242124__IMC__87_A1,1 | Lung | Primary cancer | 477 | Other | 41.7% | 0.83 | 0.47 |
| NSCLC_38242124__IMC__87_A1,10 | Lung | Primary cancer | 4,368 | Tumor/Malignant | 56.5% | 0.93 | 0.19 |
| NSCLC_38242124__IMC__87_A1,11 | Lung | Primary cancer | 3,901 | Tumor/Malignant | 77.1% | 0.98 | 0.09 |
| NSCLC_38242124__IMC__87_A1,12 | Lung | Primary cancer | 4,837 | Tumor/Malignant | 50.8% | 0.95 | 0.17 |
| NSCLC_38242124__IMC__87_A1,13 | Lung | Primary cancer | 2,263 | Tumor/Malignant | 49.9% | 0.87 | 0.37 |
| NSCLC_38242124__IMC__87_A1,14 | Lung | Primary cancer | 3,547 | Tumor/Malignant | 56.3% | 1.00 | 0.01 |
| NSCLC_38242124__IMC__87_A1,15 | Lung | Primary cancer | 4,762 | Tumor/Malignant | 55.9% | 0.95 | 0.14 |
| NSCLC_38242124__IMC__87_A1,16 | Lung | Primary cancer | 3,543 | Stromal | 32.5% | 0.41 | 0.92 |
| NSCLC_38242124__IMC__87_A1,17 | Lung | Primary cancer | 2,370 | Tumor/Malignant | 42.9% | 0.96 | 0.16 |
| NSCLC_38242124__IMC__87_A1,2 | Lung | Primary cancer | 2,918 | Stromal | 33.7% | 0.64 | 0.76 |
| NSCLC_38242124__IMC__87_A1,3 | Lung | Primary cancer | 4,326 | Tumor/Malignant | 36.7% | 0.93 | 0.18 |
| NSCLC_38242124__IMC__87_A1,4 | Lung | Primary cancer | 3,799 | Immune | 28.9% | 0.88 | 0.38 |
| NSCLC_38242124__IMC__87_A1,5 | Lung | Primary cancer | 3,344 | Tumor/Malignant | 92.4% | 1.00 | 0.02 |
| NSCLC_38242124__IMC__87_A1,6 | Lung | Primary cancer | 4,178 | Tumor/Malignant | 58.8% | 0.92 | 0.21 |
| NSCLC_38242124__IMC__87_A1,7 | Lung | Primary cancer | 3,630 | Tumor/Malignant | 73.7% | 0.96 | 0.14 |
| NSCLC_38242124__IMC__87_A1,8 | Lung | Primary cancer | 3,400 | Tumor/Malignant | 61.0% | 0.97 | 0.14 |
| NSCLC_38242124__IMC__87_A1,9 | Lung | Primary cancer | 3,996 | Stromal | 30.3% | 0.89 | 0.32 |
| NSCLC_38242124__IMC__87_A2,1 | Lung | Primary cancer | 1,284 | Other | 29.5% | 0.84 | 0.44 |
| NSCLC_38242124__IMC__87_A2,10 | Lung | Primary cancer | 2,615 | Tumor/Malignant | 63.6% | 0.97 | 0.13 |
| NSCLC_38242124__IMC__87_A2,11 | Lung | Primary cancer | 3,664 | Tumor/Malignant | 67.3% | 0.98 | 0.09 |
| NSCLC_38242124__IMC__87_A2,12 | Lung | Primary cancer | 3,796 | Tumor/Malignant | 46.9% | 0.96 | 0.15 |
| NSCLC_38242124__IMC__87_A2,13 | Lung | Primary cancer | 2,020 | Tumor/Malignant | 34.8% | 0.86 | 0.36 |
| NSCLC_38242124__IMC__87_A2,14 | Lung | Primary cancer | 3,300 | Tumor/Malignant | 62.7% | 0.96 | 0.14 |
| NSCLC_38242124__IMC__87_A2,15 | Lung | Primary cancer | 3,874 | Stromal | 33.5% | 0.52 | 0.78 |
| NSCLC_38242124__IMC__87_A2,16 | Lung | Primary cancer | 4,343 | Tumor/Malignant | 26.9% | 0.71 | 0.70 |
| NSCLC_38242124__IMC__87_A2,17 | Lung | Primary cancer | 2,873 | Stromal | 34.3% | 0.56 | 0.83 |
| NSCLC_38242124__IMC__87_A2,2 | Lung | Primary cancer | 2,830 | Stromal | 26.5% | 0.67 | 0.71 |
| NSCLC_38242124__IMC__87_A2,3 | Lung | Primary cancer | 4,628 | Tumor/Malignant | 38.9% | 0.88 | 0.30 |
| NSCLC_38242124__IMC__87_A2,4 | Lung | Primary cancer | 4,085 | Tumor/Malignant | 41.3% | 0.97 | 0.15 |
| NSCLC_38242124__IMC__87_A2,5 | Lung | Primary cancer | 3,425 | Tumor/Malignant | 50.1% | 0.96 | 0.13 |
| NSCLC_38242124__IMC__87_A2,6 | Lung | Primary cancer | 2,896 | Tumor/Malignant | 35.6% | 1.00 | 0.03 |
| NSCLC_38242124__IMC__87_A2,7 | Lung | Primary cancer | 3,691 | Tumor/Malignant | 64.7% | 0.95 | 0.19 |
| NSCLC_38242124__IMC__87_A2,8 | Lung | Primary cancer | 3,504 | Tumor/Malignant | 34.2% | 0.76 | 0.62 |
| NSCLC_38242124__IMC__87_A2,9 | Lung | Primary cancer | 954 | Stromal | 39.4% | 0.84 | 0.44 |
| NSCLC_38242124__IMC__87_A3,10 | Lung | Primary cancer | 5,265 | Tumor/Malignant | 89.3% | 1.00 | 0.02 |
| NSCLC_38242124__IMC__87_A3,11 | Lung | Primary cancer | 2,327 | Tumor/Malignant | 30.6% | 0.96 | 0.15 |
| NSCLC_38242124__IMC__87_A3,12 | Lung | Primary cancer | 1,884 | Tumor/Malignant | 73.8% | 0.99 | 0.06 |
| NSCLC_38242124__IMC__87_A3,13 | Lung | Primary cancer | 3,544 | Tumor/Malignant | 68.7% | 0.93 | 0.21 |
| NSCLC_38242124__IMC__87_A3,14 | Lung | Primary cancer | 3,812 | Tumor/Malignant | 77.6% | 0.97 | 0.09 |
| NSCLC_38242124__IMC__87_A3,15 | Lung | Primary cancer | 3,996 | Tumor/Malignant | 80.4% | 0.98 | 0.07 |
| NSCLC_38242124__IMC__87_A3,16 | Lung | Primary cancer | 3,759 | Tumor/Malignant | 84.3% | 0.99 | 0.06 |
| NSCLC_38242124__IMC__87_A3,17 | Lung | Primary cancer | 1,616 | Tumor/Malignant | 41.9% | 0.75 | 0.52 |
| NSCLC_38242124__IMC__87_A3,2 | Lung | Primary cancer | 2,387 | Tumor/Malignant | 58.0% | 0.95 | 0.17 |
| NSCLC_38242124__IMC__87_A3,3 | Lung | Primary cancer | 4,687 | Immune | 28.1% | 0.51 | 0.84 |
| NSCLC_38242124__IMC__87_A3,4 | Lung | Primary cancer | 2,759 | Tumor/Malignant | 61.4% | 0.97 | 0.13 |
| NSCLC_38242124__IMC__87_A3,5 | Lung | Primary cancer | 1,518 | Stromal | 36.7% | 0.76 | 0.57 |
| NSCLC_38242124__IMC__87_A3,6 | Lung | Primary cancer | 2,899 | Tumor/Malignant | 63.8% | 0.96 | 0.11 |